Noah William Fisher

FDA Releases New Guidance Documents On When To Submit An ANDA Or 505(b)(2) Application And On Therapeutic Equivalence Evaluations

FTC Draft Personalized-pricing Policy Would Require More Than A “personalized Price” Disclosure